Predicting treatment success with a blood test for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study looks at whether a blood test that finds tiny amounts of remaining cancer (called minimal residual disease) can help predict how well treatment works for men with prostate cancer that has spread. If you qualify, you'll help researchers understand if this test can guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 84 years old.
- You have been diagnosed with a common type of prostate cancer (like acinar, ductal, or intraductal).
- Your cancer has spread to distant parts of the body, as seen on scans.
- You have not had hormone therapy or other systemic cancer treatments before.
- You are generally in good health (can care for yourself, expected to live at least 6 months).
- Your blood counts, liver, kidney, and clotting tests are within safe ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to find microscopic cancer cells (minimal residual disease) in the blood after prostate surgery. If successful, it could help doctors decide if additional treatment is needed.
This study checks whether certain blood markers can help predict how well people with prostate cancer will respond to therapy. It may help doctors choose the most effective treatment sooner by using information from your blood.
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
This study looks for urine markers (proteins and metabolites) that may help predict how prostate cancer patients respond to treatment and what their outcomes are. You may be asked to give a urine sample and allow use of your medical and treatment details for analysis (results are not shared with you).
This study looks at men with aggressive, high-volume metastatic prostate cancer that is still sensitive to hormone therapy. It will analyze a blood test for HRR gene mutations (like BRCA) to help understand treatment patterns.
This study collects and measures “biomarkers” (measurable signs in the body) from people with prostate cancer who are about to have surgery or radiation. The goal is to understand how prostate cancer behaves during treatment, which may help improve care in the future.
Hear when a new MRD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.